GlassScriptPhysician profile
Dawn M Hansen
NPI 1558323964
$8,561.14
in general payments reported to CMS, 2019-2025
28 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $773 · 2021: $692 · 2022: $742 · 2023: $1,466 · 2024: $2,102 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,395.22 |
| Education | $326.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,864.14 | 2019-2025 | |
| Genzyme Corporation | $761.24 | 2019-2025 | |
| Ucb, INC. | $730.74 | 2020-2025 | Bimzelx |
| Janssen Biotech, INC. | $700.32 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $502.93 | 2020-2025 | Ilumya, Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $432.26 | 2024-2025 | Nemluvio |
| Dermavant Sciences, INC. | $405.65 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $328.12 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $324.24 | 2020-2025 | Otezla, Otezla, Enbrel |
| Arcutis Biotherapeutics, INC. | $312.15 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $311.45 | 2019-2025 | |
| Incyte Corporation | $282.34 | 2021-2025 | Opzelura |
| Pfizer INC. | $231.55 | 2020-2025 | |
| Leo Pharma INC. | $193.32 | 2019-2025 | Adbry |
| Organogenesis INC. | $190.66 | 2023 | Puraply |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $189.87 | 2023-2025 | Sotyktu |
| Almirall LLC | $154.71 | 2021-2025 | Klisyri |
| Lilly USA, LLC | $139.80 | 2019-2024 | Ebglyss, Taltz, Olumiant |
| Janssen Scientific Affairs, LLC | $123.05 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.67 | 2019-2023 | Arazlo |
| Hill Dermaceuticals, INC. | $71.37 | 2021-2024 | Tolak |
| Organon LLC | $60.21 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $58.10 | 2021-2025 | Xtrac |
| Sanofi-Aventis U.S. LLC | $48.99 | 2024 | |
| Mayne Pharma Commercial LLC | $29.59 | 2022-2025 | |
| Dusa Pharmaceuticals, INC. | $19.20 | 2019 | |
| Prugen, INC. Pharmaceuticals | $15.23 | 2020 | |
| Biofrontera INC. | $8.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.